医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FUJIFILM Recieves ONC HIT 2014 Edition Complete EHR Certification for Synapse RIS From ICSA Labs

2015年02月25日 AM12:00
このエントリーをはてなブックマークに追加


 

STAMFORD, Conn.

FUJIFILM Medical Systems U.S.A., Inc. has received ONC HIT 2014 Edition Complete EHR certification for Synapse RIS Version 6.3.3., which designates that the software is capable of supporting Eligible Professionals with meeting the Stage 1 and Stage 2 Meaningful Use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA). Synapse RIS Version 6.3.3., was certified by ICSA Labs, an Office of the National Coordinator-Authorized Certification Body (ONC-ACB); and is compliant in accordance with applicable criteria adopted by the Secretary of Health and Human Services (HHS). Fujifilm received certification in December 2014.

“As Meaningful Use continues to grow and evolve, Fujifilm remains committed to providing our customers with the most up-to-date information,” said Jim Morgan, vice president of Medical Informatics, FUJIFILM Medical Systems U.S.A., Inc. “Synapse RIS has integrated EHR into a powerful radiology management tool that can enhance workflow and help increase the productivity of radiology practices.”

ICSA Labs, an independent division of Verizon, offers vendor-neutral testing and certification. ONC HIT 2014 Edition Certification is granted to those technologies that are capable of meeting the more rigorous testing criteria developed to support providers and hospitals who wish to demonstrate Stage 2 meaningful use, which focuses on the capability of health IT to deliver higher quality patient care and exchange clinical information securely.

“As part of Fujifilm’s commitment to advancing the capabilities of radiologists and facilities, PENRAD Imaging benefits from continual system upgrades,” Douglas Gibson, chief executive officer at Colorado Springs Radiologists, PC and PENRAD Imaging, LLC. “Fujifilm offers a complete, fully-certified EHR with resources.”

Synapse MU, v 6.3.3’s certification number is 140243R00. ONC HIT certification conferred by ICSA Labs does not represent an endorsement of the certified EHR technology by the U.S. Department of Health and Human Services.

The clinical quality measures to which Synapse MU, v 6.3.3 has been certified include: CMS 69, CMS 117, CMS 125, CMS126, CMS 134, CMS 138, CMS 139, CMS 146, CMS 155, CMS 165 and CMS 166.

The additional software relied upon to comply with one or more of the certification criteria include: Medline Plus and Newcrop.

The additional types of costs that an eligible provider would pay to implement this Complete EHR’s capabilities in order to attempt to meet meaningful use objectives and measures include: custom interfaces.

For more information about Synapse RIS, please visit: http://www.synapseris.com/

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit www.fujimed.com and www.fujifilmendoscopy.com.

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2014, the company had global revenues of $23.9 billion, at an exchange rate of 102 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

About ONC Certification

The ONC Certified Health Information Technology (HIT) program tests and certifies that HIT is capable of meeting the 2014 Edition criteria approved by the Secretary of Health and Human Services (HHS). The certifications include Complete EHRs, which meet all of the 2014 Edition criteria for either eligible provider or hospital technology and EHR Modules, which meet one or more — but not all — of the criteria.

About ICSA Labs

ICSA Labs, an independent division of Verizon, offers third-party testing and certification of security and health IT products, as well as network-connected devices, to measure product compliance, reliability and performance for many of the world’s top security vendors. ICSA Labs is an ISO/IEC 17025:2005 accredited and 9001:2008 registered organization. ICSA Labs is NVLAP accredited as a Health IT Test Lab and is also an ONC-Authorized Certification Body (ONC-ACB) accredited by ANSI to ISO/IEC Guide 65. Visit http://www.icsalabs.com and http://www.icsalabs.com/blogs for more information.

All product and company names herein may be trademarks of their registered owners.

CONTACT

Media:
Fujifilm
Lauren Geloso, 914-789-8303
lgeloso@fujifilm.com
or
ICSA
Labs
Carlos Arcila, 908-559-8031
carlos.arcila@verizon.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗